Tucotuzumab celmoleukin
From Self-sufficiency
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Template:Infobox drug/mab source |
Target | EpCAM |
Identifiers | |
CAS Number | 339986-90-2 |
ATC code | none |
Chemical data | |
Formula | C7812H12124N2044O2408S60 |
Molar mass | 175.1 kDa[[Script error: No such module "String".]] |
Tucotuzumab celmoleukin is an anti-cancer drug. It is a fusion protein of a humanized monoclonal antibody (tucotuzumab) and an interleukin-2 (celmoleukin).[1][2][3]
This drug was developed by EMD Pharmaceuticals.
References
- ↑ Statement On A Nonproprietary Name Adopted By The Usan Council - Tucotuzumab Celmoleukin, American Medical Association.
- ↑ ClinicalTrials.gov
- ↑ National Cancer Institute: Definition of tucotuzumab celmoleukin
40x30px | This monoclonal antibody-related article is a stub. You can help ssf by expanding it. |
Categories:
- Pages with script errors
- Drugs that are a monoclonal antibody
- Infobox drug tracked parameters
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs not assigned an ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- 2Fix
- Cancer treatments
- Pages with broken file links
- Monoclonal antibody stubs